ReviewTranslational lung cancer research2017
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer.
Review in Translational lung cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Oncolytic viruses in lung cancer: mechanisms of action and research progress.Frontiers in microbiology · 2026Review
- Quantitative beam optimization for radiotherapy of peripheral lung lesions: A pilot study in stereotactic body radiotherapy.Journal of applied clinical medical physics · 2025Article
- Recent advancements in lung cancer research: a narrative review.Translational lung cancer research · 2025Review
- Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.Thoracic cancer · 2022Article
- Review
- Review
- Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA.NPJ precision oncology · 2021Article
- Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.Cancer communications (London, England) · 2021Review
- Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.Frontiers in immunology · 2020Review
- Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2019Article
- Combining stereotactic body radiation therapy with immunotherapy: current data and future directions.Translational lung cancer research · 2019Review
- The lung microenvironment: an important regulator of tumour growth and metastasis.Nature reviews. Cancer · 2019Review
- Combining immunotherapy with radiation therapy in thoracic oncology.Journal of thoracic disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality. Although a significant proportion of patients can be cured with surgery, with or without adjuvant or neoadjuvant chemotherapy and radiation, a significant proportion of patients will fail, particularly distantly. Over fifty percent of patients present with stage IV disease. There are multiple forms of immunotherapy available including T-cell transfer, cytokine therapy, and oncolytic viruses. Checkpoint inhibitors have shown tremendous activity in NSCLC and are currently under intense study given promising data on response. Immunotherapy and radiation therapy (RT) both show significant immune editing activity in NSCLC that may allow the innate and adaptive immune system to help control systemic disease by both radiosensitization and a sustained systemic immune response. Multiple clinical trials are underway exploring the role of adjuvant or neoadjuvant immunotherapy in operable NSCLC. A substantial amount of progress is to be made in terms of optimizing radiation dose and fractionation, immunotherapy type and dose, and integrating both to best realize the benefits of immunotherapy and radiation in operable lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.